RxDoctor Payments Data

Shawn Crabtree, MD

Adult Medicine · Wayne, NJNPI 1831283910

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Novo Nordisk at 33.3% of the total.

$667in general payments, 2019–2025

Across 38 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$222
  • GSK$86
  • Pfizer$80
  • Abbott$79
  • Boston Scientific$35
  • Merck$32
  • plus $134 from 7 others

What the payments were for

  • Food & beverage$667100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$667 in reported general payments places this provider in the 70th percentile of 48 adult medicine providers in New Jersey.

See all adult medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$141,986
Medicare patients
325
Services billed
1,477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$91,000
TrulicityDulaglutide25$34,642
MounjaroTirzepatide30$32,918
JanuviaSitagliptin Phosphate25$28,324
JardianceEmpagliflozin22$25,878
JanumetSitagliptin Phos/Metformin Hcl11$17,874
EliquisApixaban18$13,645
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,200
Dexlansoprazole DrDexlansoprazole17$4,299
Levothyroxine Sodium277$2,953
Rosuvastatin Calcium210$2,730
Albuterol Sulfate HfaAlbuterol Sulfate88$2,729
Atorvastatin Calcium319$2,244
Valsartan55$2,219
Amlodipine Besylate270$2,053

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$222$91,00088 claims
MerckJanuvia, Janumet$32$46,19836 claims
PfizerEliquis$80$13,64518 claims
GSKTrelegy Ellipta$86$7,20011 claims
AbbVieSynthroid$20$1,63233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 48 adult medicine providers in New Jersey.

Other adult medicine in Wayne

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →